The Time Back campaign for cancer care honors oncologists, the emotional burdens they carry, and the work they do to help make more moments possible for people living with cancer. 

https://www.bms.com/healthcare-providers/time-back-campaign-honoring-oncologists-in-cancer-care.html

Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer

ASCENT-04 published in New England Journal of Medicine: 

https://www.nejm.org/doi/full/10.1056/NEJMoa2508959

Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer

ASCENT-03 published in New England Journal of Medicine: 

https://www.nejm.org/doi/full/10.1056/NEJMoa2511734

This brochure from Regeneron provides helpful information on advanced CSCC and advanced BCC in patients of color.

Joint initiative to focus on expanding early detection and equitable access to care through lung cancer specific AI workflows on Microsoft’s suite of radiology solutions

Study marks the first positive Phase 3 study for mezigdomide and the second positive Phase 3 study for the Bristol Myers Squibb CELMoD program. 

In addition to surgery, with the evolution of new treatment options, surgeons play a role in referral of patients to medical oncologists or the multidisciplinary team. Coordination with the medical oncologist and the entire care team can help facilitate the development of a treatment plan for patients. The resource will review some factors that may be relevant when considering neoadjuvant and adjuvant therapies.

Published on: February 17, 2025

Watch Dr. David Sallman, a leading MDS specialist at the Moffitt Cancer Center, talk about the importance of investigating unexplained anemia.

Consider updating your billing software to reflect the permanent J-code for RYTELO, J0870, and units: 1 unit per 1 mg, so J-code can be used on or after January 1, 2025.


Too often, women with endometrial cancer (EC) have reported that their symptoms were stigmatized and dismissed. Even though diagnoses and deaths from this type of uterine cancer are on the rise, EC remains under-recognized.

Spot Her® is an initiative to help end the silence around EC and empower all people across generations and cultures to speak up, take action, and spot the potential signs at an early stage—when EC may be more treatable.






The purpose of this Toolkit is to help support your experience as someone living with Diffuse Large B-Cell Lymphoma (DLBCL) or as a care partner by providing information to help you build a deeper understanding of DLBCL. This Toolkit was created by a group of patients, care partners, advocates and healthcare professionals brought together by Incyte, a pharmaceutical company working on behalf of the DLBCL community.


This resource was created by Patient Resource and GO2 for Lung Cancer and produced with support from 

 to provide patients and their loved ones with comprehensive information to guide them throughout their journey with small cell lung cancer. A Spanish-speaking version is available via download.
Free copies of this resource can be obtained by ordering it by:

Educational Resources

Educational Resources

Bristol Myers Squibb’s Time Back campaign honors the most precious gift oncologists provide in cancer care: time

View these recent articles in the New England Journal of Medicine from our member

2026 Regeneron The Different Colors of Skin Cancer Brochure

Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer

Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma

CONSIDERATIONS FOR NEOADJUVANT AND ADJUVANT THERAPY

Anemia in Focus: The Challenge of Identifying Myelodysplastic Syndromes (MDS)

Centers for Medicare & Medicaid Services has assigned a permanent J-code for RYTELO

Genentech-Pro: Product, Access, and Disease State Resources for Providers & Patients

Small Moments Can Help You Spot Endometrial Cancer